Zijian Li

Zijian Li

Auto-generated profile, based on publicly available information

Zijian Li

Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in International Immunopharmacology
Verified
Journal Article
Closed access
ZLZijian Li
Zijian Li
FLFei Liu
Fei Liu
XHXin He
Xin He
XYXue Yang
Xue Yang
FSFengping Shan
Fengping Shan
JFJuan Feng
Juan Feng


1 August 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
ZLZijian Li
Zijian Li
YYYue You
Yue You
NGNoreen Griffin
Noreen Griffin
JFJuan Feng
Juan Feng
FSFengping Shan
Fengping Shan

3 August 2020 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ZLZijian Li
Zijian Li
YCYueran Cui
Yueran Cui
JFJuan Feng
Juan Feng
YGYanxia Guo
Yanxia Guo
Background: Ischemic stroke (IS) is the second leading cause of death worldwide which is a serious hazard to human health. Evidence suggests that the immune system plays a key role in the pathophysiology of IS. However, the precisely immune related mechanisms were still not been systematically understood. Methods: In this study, we aim to identify the immune related modules and genes that might play vital role in the occurrence and development of IS by using the weighted gene co-expression network analysis (WGCNA). Meanwhile, we applied a kind of deconvolution algorithm to reveal the proportions of 22 subsets of immune cells in the blood samples. Results: There were total 128 IS patients and 67 healthy control samples in the three Gene Expression Omnibus (GEO) datasets. Under the screening criteria, 1082 DEGs (894 up-regulated and 188 down-regulated) were chosen for further analysis. A total of 11 clinically significant modules were identified, from which immune-related hub modules and hub genes were further explored. Finally, 16 genes were selected as real hub genes for further validation analysis. Furthermore, these CIBERSORT results suggest that detailed analysis of the immune subtype distribution pattern has the potential to enhance clinical prediction and to identify candidates for immunotherapy. More specifically, we identified that neutrophil emerge as a promising target for IS therapies. Conclusions: In the present study, we investigated the immune related gene expression modules, in which the SLAMF1, IL7R and NCF4 may be novel therapeutic targets to promote functional and histological recovery after ischemic stroke. Furthermore, these hub genes and neutrophils may become important biological targets in the drug screening and drug designing.

10 February 2023 in Science Advances
Verified
Journal Article
Closed access
WYWu Yin
Wu Yin
ZLZijian Li
Zijian Li
YCYan Chen
Yan Chen
FYFangzhou Yin
Fangzhou Yin
XJXiaojun Ji
Xiaojun Ji
WYWu Yin
Wu Yin
Dysregulated endocrine hormones (EHs) contribute to tumorigenesis, but how EHs affect the tumor immune microenvironment (TIM) and the immunotherapy of non–small cell lung cancer (NSCLC) is still unclear. Here, endogenous ouabain (EO), an adrenergic hormone, is elevated in patients with NSCLC and closely related to tumor pathological stage, metastasis, and survival. EO promotes the suppression of TIM in vivo by modulating the expression of immune checkpoint proteins, in which programmed cell death protein ligand 1 (PD-L1) plays a major role. EO increases PD-L1 transcription; however, the EO receptor Na- and K-dependent adenosine triphosphatase (Na, K-ATPase) α1 interacts with PD-L1 to trigger the endocytic degradation of PD-L1. This seemingly contradictory result led us to discover the mechanism whereby EO cooperates with Na, K-ATPase α1 to finely control PD-L1 expression and dampen tumoral immunity. In conclusion, the Na, K-ATPase α1/EO signaling facilitates immune escape in lung cancer, and manipulation of this signaling shows great promise in improving immunotherapy for lung adenocarcinoma.

1 October 2018 in Cytotherapy
Verified
Journal Article
Closed access
WWWenting Wang
Wenting Wang
ZLZijian Li
Zijian Li
JFJuan Feng
Juan Feng